glp-1 tirzepatide FDA says shortage of is over Compounded Tirzepatide Program: Results, Timeline

Instances of contamination and improper dosing are not uncommon, and the consequences can be severe

Novo Nordisk filed the New Drug Application (NDA) for CagriSema in early 2026, based on positive results from the REDEFINE phase 3 trial program

doi: 10.1038/s41368-024-00329-5 191 DengYChenXZhangZZhaoXZhuZWuCet al

investigated the protective effects of gene therapy, namely the overexpression of the GPX in stroke induction, which effectively decreased the release of the proapoptotic protein cytochrome C and increased the neuronal survival ratio (Figure 3D) [91]

NETs and neutrophilderived proteases are increasingly recognized as drivers of hepatic steatosis and pancreatic cell stress, contributing to the metabolic derangements seen in PCOS (e.g., nonalcoholic fatty liver disease and cell dysfunction) [92]